What Happened?
Shares of healthcare data analytics company Health Catalyst (NASDAQ: HCAT) fell 4.2% in the afternoon session after Wells Fargo downgraded the company's stock to Equal Weight from Overweight and significantly cut its price target.
The firm lowered its price target to $1.00 from $5.00, citing concerns about structural issues that may continue even after the company's replatforming efforts. The bank noted that Health Catalyst had missed expectations for both client retention and growth. This action followed the company's recent financial report for the fourth quarter of 2025, which presented mixed results. While revenue surpassed expectations, earnings per share of $0.08 fell short of forecasts. Furthermore, the company provided a weak revenue outlook for the first quarter of 2026, projecting a decline.
The shares closed the day at $1.16, down 1.3% from previous close.
The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Health Catalyst? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Health Catalyst’s shares are extremely volatile and have had 48 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The previous big move we wrote about was 14 days ago when the stock gained 12.4% on the news that a broad rally continued to suggest renewed investor interest in the sector. The move was part of a wider trend that saw the broader software ETF (IGV) outperform the NASDAQ by 9% in the preceding week. This rally followed a period where software stocks had lagged the market. According to analysis from Morgan Stanley, investors were shifting their focus from general artificial intelligence excitement to software companies that provided practical and secure solutions for businesses. The firm noted that enterprise AI adoption was concentrated in targeted uses like software development and information retrieval, signaling a more mature phase of investment in the space.
Health Catalyst is down 49.3% since the beginning of the year, and at $1.16 per share, it is trading 74.9% below its 52-week high of $4.60 from March 2025. Investors who bought $1,000 worth of Health Catalyst’s shares 5 years ago would now be looking at only $24.77.
ONE MORE THING: 3 Hidden Platforms Growing 3X Faster than Amazon, Google, and PayPal. Amazon, Google, and Meta all followed the same playbook: Dominate an ignored market. Build an unbeatable moat. Scale until you’re unstoppable.
These three platforms are running that exact playbook right now. The early investors in Amazon made fortunes. The early investors in these could do the same. Get All 3 Stocks Here for FREE.
